Biosimilars/General

Canada's path to biosimilar adoption and healthcare accessibility: insights from British Columbia

Biosimilars/General | Posted 19/06/2024

Canada’s British Columbia transitioned to biosimilars in November 2019, achieving significant cost savings reinvested in BC PharmaCare. This initiative has improved drug coverage, expanding access to various medications and medical devices.

Disruption in the US adalimumab market

Biosimilars/General | Posted 05/06/2024

In April 2024, Evernorth Health Services in the US announced that a biosimilar of AbbVie’s Humira ( adalimumab) will be available for US$0 out of pocket for eligible patients of its specialty pharmacy, Accredo. This announcement follows the news that prescriptions for adalimumab biosimilars have spiked to 36% after leading pharmacy benefit manager CVS Caremark removed the branded reference product from its major national commercial formularies in January 2024.

Addressing the persistent gap in Medicare access to Humira biosimilars

Biosimilars/General | Posted 16/04/2024

In an article by Dr Joshua Cohen, he discusses the challenges facing the adoption of biosimilars in the US, particularly focusing on Medicare beneficiaries' access to these lower-cost alternatives to brand-name biologics like Humira. 

Biosimilars of omalizumab

Biosimilars/General | Posted 19/08/2016

Last update: 3 November 2017

Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes [1]. Unlike an ordinary anti-IgE antibody, it does not bind to IgE that is already bound by the high affinity IgE receptor (FcεRI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells.

Brazil advances in follow-on biologicals/biosimilars approvals, trailing Europe

Biosimilars/General | Posted 09/02/2024

Brazil is the fourth-largest market in terms of approved follow-on biological medications worldwide. As of May 2023, Brazil has approved 52 follow-on biological medicines [1] and approximately 30 biological products awaiting testing or already being tested by the Brazilian Health Regulatory Agency, ANVISA (Agência Nacional de Vigilância Sanitária) [2].

Insurer perspective on increasing biosimilar uptake in Canada

Biosimilars/General | Posted 06/02/2024

In November 2023, Canada’s Prince Edward Island (PEI) became the 11th Canadian jurisdiction to announce the adoption of biosimilars switching policies [1-10]. This follows the trend in Canada, to try to increase the uptake of biosimilars.

CVS Caremark removes Humira in the US and Sandoz launches Hyrimoz in Europe

Biosimilars/General | Posted 30/01/2024

It has been announced that the US’ CSV Caremark, a CVS Health company and one of the country’s largest pharmacy benefit managers (PBMs), will remove AbbVie’s Humira (adalimumab), from its major national commercial formularies effective 1 April 2024, in favour of biosimilar options. In Europe, Sandoz has launched its biosimilar Hyrimoz (adalimumab), a citrate-free high-concentration formulation (HCF) indicated for all conditions of the reference medicine. 

Biosimilars of adalimumab

Biosimilars/General | Posted 03/10/2014

Last update: 11 March 2024

Adalimumab is a human monoclonal antibody that treats autoimmune diseases by inhibiting tumour necrosis factor (TNF); a soluble inflammatory cytokine. Adalimumab binds to TNF-alpha (TNF-α), preventing it from activating TNF receptors, which cause the inflammatory reactions associated with autoimmune diseases. Adalimumab is indicated for the treatment of rheumatoid, juvenile idiopathic and psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, psoriasis and ulcerative colitis.

Canada’s Prince Edward Island adopts biosimilars switching policy

Biosimilars/General | Posted 07/11/2023

Canada’s Prince Edward Island (PEI) becomes the 11th Canadian jurisdiction to announce the adoption of biosimilars switching policies. 

ASCO policy statement on biosimilars and interchangeables in oncology updated

Biosimilars/General | Posted 24/10/2023

The American Society of Clinical Oncology (ASCO) has released a new policy statement on the use of biosimilar and interchangeable products in oncology.

The statement proposes guidance and recommendations for stakeholders, including manufacturers, payers, regulatory agencies, clinicians, and patients, to ensure equitable access to high-quality care and to address challenges to biosimilar uptake [1].